Amgen to announce data on obesity drug MariTide at healthcare conference

Core Insights - Amgen's research chief expressed strong confidence in the company's experimental obesity drug MariTide, indicating positive expectations for its efficacy in weight maintenance [1] Company Summary - Amgen is preparing to unveil results from a mid-stage trial extension for MariTide, aimed at demonstrating the drug's effectiveness in helping individuals maintain weight loss [1]